The biologics pipeline is becoming increasingly complex as next generation antibody formats, including bispecific antibodies, move rapidly toward the clinic. For early stage biotech teams, this complexity often translates into uncertainty around where the true development risks lie, how early decisions influence IND readiness, and how to progress quickly without creating downstream rework.
Drawing on development experience from more than 70 bispecific antibody programs, Lonza technical experts will share recurring patterns observed across analytical development, downstream purification, and drug product formulation. The session will highlight common issues that frequently emerge in early development of complex biologics and explain how they could escalate into timeline, CMC, or IND related risks if not addressed proactively.
The webinar will focus on three core development domains—analytical development, downstream purification, and drug product formulation—and discuss where established platform approaches can accelerate progress, and where customized strategies are required to manage molecule specific risks. Practical examples will illustrate how early development choices can support both speed and robustness as programs advance toward the clinic and beyond.
